Kestra Medical (KMTS) Fundamental Analysis: Revenue, Earnings & Valuation

0.50 / 10

Underperform

Fundamental rating is Underperform with a 0.5/10 score, indicating subpar health. Asset‑MV and Profit‑MV show modest strength, while Revenue‑MV, Cash‑MV and profitability ratios are weak. Overall fund score 0.5 and negative factor weights confirm fragile fundamentals.

Analysis Checks(2/10)

Revenue-MV

Value-2.38

Score0/3

Weight28.51%

1M Return-4.18%

ROA (%)

Value-66.62

Score0/3

Weight31.49%

1M Return-6.58%

Net cash flow from operating activities / Operating revenue (%)

Value-129.75

Score1/3

Weight9.37%

1M Return-1.35%

Profit-MV

Value0.66

Score2/3

Weight-26.93%

1M Return3.09%

Annualized net profit margin on total assets (%)

Value-66.62

Score0/3

Weight31.49%

1M Return-6.58%

EBIT / Total operating revenue (%)

Value-182.47

Score1/3

Weight5.30%

1M Return-0.83%

Asset-MV

Value-1.83

Score3/3

Weight-40.90%

1M Return4.62%

Net profit / Total operating revenue (%)

Value-190.28

Score1/3

Weight6.05%

1M Return-0.84%

Cash-MV

Value0.02

Score1/3

Weight25.52%

1M Return-4.16%

Net profit / Total profit (%)

Value100.12

Score0/3

Weight30.09%

1M Return-4.52%

Is KMTS undervalued or overvalued?

KMTS scores 0.50/10 on fundamentals and holds a Premium valuation at present. Backed by its -37.61% ROE, -171.87% net margin, -8.00 P/E ratio, 4.11 P/B ratio, and 30.33% earnings growth, these metrics solidify its Underperform investment rating.